Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dysregulated mTOR networks in experimental sporadic Alzheimer’s disease

25 Sept 2024

Abstract excerpt

Background Beyond the signature amyloid-beta plaques and neurofibrillary tangles, Alzheimer’s disease (AD) has been shown to exhibit dysregulated metabolic signaling through insulin and insulin-like growth factor (IGF) networks that crosstalk with the mechanistic target of rapamycin (mTOR). Its broad impact on brain structure and function suggests that mTOR is likely an important therapeutic target for AD....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Neurological Disease Mechanisms and Treatments
Share to Neurological disorders and treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39386180
DOI: 10.3389/fncel.2024.1432359

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dysregulated mTOR networks in experimental sporadic Alzheimer’s diseasePMID 39386180Read ↗

Dysfunction of the mTOR pathway is a risk factor for Alzheimer’s diseaseSemantic proximity Read ↗

<scp>mTOR</scp> regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathiesSemantic proximity Read ↗

Taking aim at Alzheimer's disease through the mammalian target of rapamycinSemantic proximity Read ↗

mTOR Mysteries: Nuances and Questions About the Mechanistic Target of Rapamycin in NeurodegenerationSemantic proximity Read ↗

The mammalian target of rapamycin at the crossroad between cognitive aging and Alzheimer’s diseaseSemantic proximity Read ↗

Targeting mTOR restores tau-induced metabolic, mitochondrial, and cognitive deficits in a tauopathy mouse modelSemantic proximity Read ↗

Genetic reduction of mammalian target of rapamycin ameliorates Alzheimer's disease-like cognitive and pathological deficits by restoring hippocampal gene expression signature.Semantic proximity Read ↗

Longevity Pathways (mTOR, SIRT, Insulin/IGF-1) as Key Modulatory Targets on Aging and NeurodegenerationSemantic proximity Read ↗

mTOR signaling as a molecular target for the alleviation of Alzheimer's disease pathogenesisSemantic proximity Read ↗

Molecular interplay between hyperactive mammalian target of rapamycin signaling and Alzheimer’s disease neuropathology in the NS-Pten knockout mouse modelSemantic proximity Read ↗

Dysregulated mTOR-dependent signaling in neurodegeneration or carcinogenesis: implication for Alzheimer's disease and brain tumors.Semantic proximity Read ↗

mTOR in Alzheimer disease and its earlier stages: Links to oxidative damage in the progression of this dementing disorderSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.